Search results (83)
« Back to NewsThe latest news, stories and exciting findings from across the Oxford cancer research community
Oxford Cancer Announces 2025 CRIS Cancer Clinical Career Fellows
13 October 2025
Oxford Cancer, together with the CRIS Cancer Foundation, is delighted to announce the appointment of the 2025 CRIS Cancer Postdoctoral Clinical Fellows: Dr Rebecca Ling and Dr Casmir Turnquist. Both Fellows will lead on two distinct projects focused on childhood cancer.
Dr Peter Wan Awarded Pancreatic Cancer UK Fellowship to Develop New Immunotherapy for Pancreatic Cancer
9 October 2025
Dr Peter Kok-Ting Wan, PhD, postdoctoral researcher at the Department of Oncology, has been awarded a prestigious fellowship from Pancreatic Cancer UK to develop a new immunotherapy for pancreatic cancer, which has the lowest survival rate of any common cancer
Iron Levels Found to Play a Key Role in FLASH Radiotherapy’s Tissue-Sparing Effect
16 September 2025
Researchers in the Department of Oncology have uncovered new insights into how FLASH radiation therapy (RT) kills cancer cells while minimising damage to healthy tissues. The study, led by Dr Ejung Moon in collaboration with Dr Kristoffer Petersson, has demonstrated that FLASH RT induces iron-dependent cell death in tumour cells but not in healthy cells, which may contribute to its tissue sparing effect. Notably, tissue iron levels were shown to critically influence this process, opening new avenues of investigation into which cancer types may benefit most from this promising therapeutic technique.
Scientists reveal how cells repair toxic DNA damage linked to cancer and premature ageing
4 August 2025
Researchers at the University of Oxford and Nanyang Technological University, Singapore have uncovered the mechanism by which cells identify and repair a highly toxic form of DNA damage that causes cancer, neurodegeneration, and premature ageing.
Study finds potential path to treatment for an aggressive form of leukaemia
18 June 2025
In a collaborative new study, researchers at Ludwig Cancer Research Oxford have identified a potential new therapeutic target in blast phase myeloproliferative neoplasm, a particularly aggressive and hard-to-treat form of leukaemia.
The stellar mission taking on cellular plasticity in bowel cancer
18 June 2025
Backed by £5.5m of funding from CRUK and its partners, the hugely ambitious CRC-STARS programme - which is co-lead by Professor Simon Leedham in the Nuffeild Department of Medicine - aims to revolutionise how bowel cancer is treated.
New research reveals druggable target arising from chromosomal rearrangement in aggressive leukaemia
10 June 2025
Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes
23 April 2025
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
Pancreatic cancer immune map provides clues for precision treatment targeting
6 February 2025
New research - published today in Nature Communications - shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
Predicting Response to Rectal Cancer Treatment through the S:CORT consortium
5 December 2024
Recent research from the S:CORT team spanning three publications has identified key biomarkers and treatment strategies that predict and enhance effectiveness of radiotherapy in rectal cancer treatment.
Researchers develop new tool to better predict AML outcomes in older patients
17 September 2024
In a study published in the Journal of Clinical Oncology, an international research team has used machine learning to improve risk stratification for patients over 60 diagnosed with acute myeloid leukaemia, an aggressive type of blood cancer.
Oxford Cancer: 5 minutes with Professor Dame Molly Stevens
23 May 2024
Professor Dame Molly Stevens is John Black Professor of Bionanoscience in the Department of Physiology, Anatomy and Genetics and the Institute of Biomedical Engineering. She recently moved her lab from Imperial College London to the University of Oxford and the Kavli Institute for nanoscience discovery, and she is joining the Oxford Cancer community.
OCION Funding Scheme: In conversation with David Church and Luciana Gneo
10 May 2024
The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardees, David Church and Luciana Gneo, to discuss what research the fund will enable them to carry out.
Research team receives $25m Cancer Grand Challenges award
7 March 2024
A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle the solid tumours in children challenge.
World Cancer Day: Oxford University professors on the record with their contribution to the fight against cancer
4 February 2024
Principal Investigators at the University talk candidly about their work and how they’re helping the fight against cancer.
AI-based method provides insights for predicting colorectal cancer outcomes
2 February 2024
The largest multiparameter immunoprofiling study in cancer to date has suggested an underappreciated role of a subset of immune cells in determining the risk of bowel cancer relapse after surgery.
Oxford University Hospitals launches new mRNA cancer vaccine trial for patients with head and neck cancers
11 December 2023
The first patient in Oxfordshire has been treated in an mRNA cancer vaccine trial at Oxford University Hospitals NHS Foundation trust (OUH). The trial, led locally by Dr Ketan Shah, consultant clinical oncologist at OUH, marks a significant milestone in the national cancer vaccine advance.
New discovery furthers our understanding of how critical immune cells are controlled during an infection
7 November 2023
A recent publication from Audrey Gérard’s lab looks at how a specific protein, called IFNγ, can coordinate CD8+ T cell responses during a flu infection.
Researchers discover how cancer cells adapt under acidity
30 June 2023
New research led by Dr Johanna Michl and Professor Pawel Swietach has solved the longstanding mystery of how cancer cells are able to maintain a relatively alkaline intracellular pH, despite being surrounded by an acidic environment.
Hypertension drugs could improve cancer immunotherapy efficacy
13 June 2023
Researchers from Oxford's Ludwig Institute for Cancer Research and de Duve Institute have found out that drugs used to treat hypertension could substantially improve the clinical efficacy of cancer immunotherapy. They discovered a new treatment approach that helps T lymphocytes to destroy cancerous cells.